Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Background: The Centers for Disease Control and Prevention (CDC) reports that 42% of adults in the United States (US) are obese, and 10% are severely obese. Obesity has many known associated health risks, and successful treatment decreases those risks. Management always includes diet and lifestyle...
Saved in:
Main Authors: | Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser |
---|---|
Format: | Article |
Language: | English |
Published: |
The University of Toledo
2025-02-01
|
Series: | Translation |
Subjects: | |
Online Access: | https://openjournals.utoledo.edu/index.php/translation/article/view/1218 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01) -
Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01) -
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
by: Tohada M. AL-Noshokaty, et al.
Published: (2025-06-01) -
Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01) -
Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
by: Xu He, et al.
Published: (2025-01-01)